Yasuhiro Sakashita

Dr. Yasuhiro Sakashita

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2025 in The FASEB Journal
Verified
Journal Article
Open access
DMDaiki Muramatsu
Daiki Muramatsu
TNTakahiro Nakayama
Takahiro Nakayama
MTMayumi Tsuji
Mayumi Tsuji
KUKenichi Umeda
Kenichi Umeda
SHSadao Hikishima
Sadao Hikishima
Kenjiro OnoKenjiro Ono
Kenjiro Ono
Alzheimer's disease (AD) is the most prevalent age‐related neurodegenerative disorder, mainly characterized by amyloid β (Aβ) accumulation in the brain. Numerous new agents are currently undergoing clinical trials as disease‐modifying therapies (DMTs) targeting Aβ. ALZ‐801 is a promising candidate DMT for AD, with a phase 3 trial of ALZ‐801 ongoing specifically for apolipoprotein E (APOE) ε4 homozygous patients with early‐stage AD. This study aimed to examine the effects of ALZ‐801 on Aβ assembly and explore its toxicological profile. Thioflavin T (ThT) assays and two imaging modalities—transmission electron microscopy (TEM) and high‐speed atomic force microscopy (HS‐AFM)—were used to evaluate ALZ‐801's effects on Aβ assembly. To assess the effect of ALZ‐801 on Aβ 42 ‐induced cytotoxicity, 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide (MTT) assays and lactate dehydrogenase (LDH) assays were performed. ThT assays revealed increased lag time and decreased fluorescence in the presence of ALZ‐801, confirming inhibition of Aβ 42 fibril formation, as confirmed by TEM. Real‐time observation using HS‐AFM revealed that ALZ‐801 inhibited the formation of Aβ 42 fibril from low‐molecular‐weight (LMW)‐Aβ 42 in the presence of Aβ 42 seeds. HS‐AFM also revealed that globular aggregates from LMW‐Aβ 42 were significantly larger with ALZ‐801, with few fibrils noted. MTT and LDH assays indicated that ALZ‐801 prevented LMW‐Aβ 42 ‐induced cytotoxicity but did not reduce cytotoxicity induced by high‐molecular‐weight‐Aβ 42 . ALZ‐801 can inhibit Aβ 42 aggregation by preventing both nucleus formation and fibril elongation, while promoting large globular oligomer formation, and can significantly reduce LMW‐Aβ 42 ‐induced cytotoxicity. These findings underscore the potential of ALZ‐801 as an effective DMT for APOE ε4 homozygous patients with AD.

1 January 2019 in Japanese Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
KNKeisuke Nonaka
Keisuke Nonaka
YMYoko Matsuda
Yoko Matsuda
MKMototsune Kakizaki
Mototsune Kakizaki
STShoichiro Takakuma
Shoichiro Takakuma
AHAkihiko Hamamatsu
Akihiko Hamamatsu
TATomio Arai
Tomio Arai
An 84-year-old man with chronic renal failure, anemia, and diabetes was admitted for hemodialysis initiation. His vital signs were stable until the eighteenth hospital day, before having an influenza A virus infection. Three days later, he died of septic shock with severe liver impairment. His leukocyte count, prothrombin time (PT-INR), and liver enzymes, such as AST and ALT, were significantly increased. Hypercytokinemia was also observed. Autopsy revealed bilateral diffuse pneumonia with neutrophil infiltration. The liver showed extensive centrilobular hepatocyte necrosis. Immunohistochemistry for influenza A nucleoprotein was positive in the ciliated columnar epithelium of the bronchi and negative in the trachea, lungs, and liver. Hypoxic hepatitis is characterized by an abrupt and massive increase in aminotransferase levels (more than 20 times of the upper normal limit) due to the anoxic centrilobular hepatocyte necrosis. The occurrence of hypoxic hepatitis requires a pre-existing, chronic condition, such as anemia, causing less oxygen supply to the liver, followed by an acute drop in hepatic oxygen supply, such as septic shock. Therefore, this report suggests that hypoxic hepatitis can be an important causative factor for acute liver failure associated with influenza virus infection.

21 October 2021 in Neuropathology
Verified
Journal Article
Closed access
PDF file
YSYasuhiro Sakashita
Yasuhiro Sakashita
TMTomoyasu Matsubara
Tomoyasu Matsubara
TTTadayuki Takata
Tadayuki Takata
ZTZen‐Ichi Tanei
Zen‐Ichi Tanei
AMAtsuko Motoda
Atsuko Motoda
SMShigeo Murayama
Shigeo Murayama

1 June 2017 in Journal of the Neurological Sciences
Verified
Journal Article
Closed access
YSYasuhiro Sakashita
Yasuhiro Sakashita
THToshio Hamada
Toshio Hamada
TMTomohiko Machiya
Tomohiko Machiya
MYMasahito Yamada
Masahito Yamada

29 April 2022 in Clinical Neurology and Neurosurgery
Verified
Journal Article
Closed access
YSYasuhiro Sakashita
Yasuhiro Sakashita
INIchiro Nozaki
Ichiro Nozaki
THTsuyoshi Hamaguchi
Tsuyoshi Hamaguchi
AKAkio Kimura
Akio Kimura
TSTakayoshi Shimohata
Takayoshi Shimohata
Kenjiro OnoKenjiro Ono
Kenjiro Ono

28 August 2026 in The Journal Of Prevention of Alzheimer's Disease
Verified
Journal Article
Open access
Moeko Noguchi-ShinoharaMoeko Noguchi-Shinohara
Moeko Noguchi-Shinohara
DMDaiki Muramatsu
Daiki Muramatsu
ASAyano Shima
Ayano Shima
YSYasuhiro Sakashita
Yasuhiro Sakashita
YTYasutake Tada
Yasutake Tada
Kenjiro OnoKenjiro Ono
Kenjiro Ono